Liquidity and Capital Resources	9 Months Ended
Sep. 30, 2013
Liquidity and Capital Resources [Abstract]
Liquidity and Capital Resources	9. Liquidity and Capital Resources At September 30, 2013, the Company had cash and cash equivalents of approximately $6.0 million and short-term investments of approximately $17.0 million. Management believes that the Company’s current cash on hand and short-term investments, along with approximately $24.1 million of net proceeds received from the Company’s underwritten public offering on October 15, 2013 described in Note 11, will be sufficient to fund its operations for the foreseeable future. The estimate is based, in part, upon the Company’s currently projected expenditures for the remainder of 2013 and the first nine months of 2014 of approximately $28.2 million, which includes approximately $16.2 million for its clinical programs for aldoxorubicin, approximately $0.3 million for other programs, approximately $4.8 million for general operation of its clinical programs, and approximately $6.9 million for other general and administrative expenses. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections. If the Company obtains marketing approval and successfully commercializes aldoxorubicin or other product candidates, the Company anticipates it will take several years, and possibly longer, for it to generate significant recurring revenue. The Company will be dependent on future financing and possible strategic partnerships or asset sales until such time, if ever, as it can generate significant recurring revenue. The Company has no commitments from third parties to provide any additional financing, and it may not be able to obtain future financing on favorable terms, or at all. If the Company fails to obtain sufficient funding when needed, it may be forced to delay, scale back or eliminate all or a portion of its development programs or clinical trials, seek to license to other companies its product candidates or technologies that it would prefer to develop and commercialize itself, or seek to sell some or all of its assets or merge with or be acquired by another company.

9. Liquidity and Capital Resources

At September 30, 2013, the Company had cash and cash equivalents of approximately $6.0 million and short-term investments of approximately $17.0 million. Management believes that the Company’s current cash on hand and short-term investments, along with approximately $24.1 million of net proceeds received from the Company’s underwritten public offering on October 15, 2013 described in Note 11, will be sufficient to fund its operations for the foreseeable future. The estimate is based, in part, upon the Company’s currently projected expenditures for the remainder of 2013 and the first nine months of 2014 of approximately $28.2 million, which includes approximately $16.2 million for its clinical programs for aldoxorubicin, approximately $0.3 million for other programs, approximately $4.8 million for general operation of its clinical programs, and approximately $6.9 million for other general and administrative expenses. These projected expenditures are also based upon numerous other assumptions and subject to many uncertainties, and our actual expenditures may be significantly different from these projections.

If the Company obtains marketing approval and successfully commercializes aldoxorubicin or other product candidates, the Company anticipates it will take several years, and possibly longer, for it to generate significant recurring revenue. The Company will be dependent on future financing and possible strategic partnerships or asset sales until such time, if ever, as it can generate significant recurring revenue. The Company has no commitments from third parties to provide any additional financing, and it may not be able to obtain future financing on favorable terms, or at all. If the Company fails to obtain sufficient funding when needed, it may be forced to delay, scale back or eliminate all or a portion of its development programs or clinical trials, seek to license to other companies its product candidates or technologies that it would prefer to develop and commercialize itself, or seek to sell some or all of its assets or merge with or be acquired by another company.